{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01392625",
      "OrgStudyIdInfo": {
        "OrgStudyId": "20100968"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "1R01HL110737-01",
            "SecondaryIdType": "U.S. NIH Grant/Contract",
            "SecondaryIdLink": "https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01HL110737-01&Fy=all"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "University of Miami",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)",
      "OfficialTitle": "A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Dilated Cardiomyopathy.",
      "Acronym": "PoseidonDCM"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2018",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 19, 2011",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "August 28, 2016",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "August 28, 2017",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "June 29, 2011",
      "StudyFirstSubmitQCDate": "July 11, 2011",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 12, 2011",
        "StudyFirstPostDateType": "Estimate"
      },
      "ResultsFirstSubmitDate": "August 3, 2017",
      "ResultsFirstSubmitQCDate": "January 19, 2018",
      "ResultsFirstPostDateStruct": {
        "ResultsFirstPostDate": "February 15, 2018",
        "ResultsFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "January 19, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 15, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Joshua M Hare",
        "ResponsiblePartyInvestigatorTitle": "Sponsor- Investigator; Director of ISCI, Chief Science Officer",
        "ResponsiblePartyInvestigatorAffiliation": "University of Miami"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Joshua M Hare",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "National Heart, Lung, and Blood Institute (NHLBI)",
            "CollaboratorClass": "NIH"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The technique of transplanting progenitor cells into a region of damaged myocardium, termed cellular cardiomyoplasty1, is a potentially new therapeutic modality designed to replace or repair necrotic, scarred, or dysfunctional myocardium2-4. Ideally, graft cells should be readily available, easy to culture to ensure adequate quantities for transplantation, and able to survive in host myocardium; often a hostile environment of limited blood supply and immunorejection. Whether effective cellular regenerative strategies require that administered cells differentiate into adult cardiomyocytes and couple electromechanically with the surrounding myocardium is increasingly controversial and recent evidence suggests that this may not be required for effective cardiac repair. Most importantly, transplantation of graft cells should improve cardiac function and prevent adverse ventricular remodeling. To date, a number of candidate cells have been transplanted in experimental models, including fetal and neonatal cardiomyocytes5, embryonic stem cell-derived myocytes6, 7, tissue engineered contractile grafts8, skeletal myoblasts9, several cell types derived from adult bone marrow10-15, and cardiac precursors residing within the heart itself16. There has been substantial clinical development in the use of whole bone marrow and skeletal myoblast preparations in studies enrolling both post-infarction patients, and patients with chronic ischemic left ventricular dysfunction and heart failure. The effects of bone-marrow derived mesenchymal stem cells (MSCs) have also been studied clinically.\n\nCurrently, bone marrow or bone marrow-derived cells represent highly promising modality for cardiac repair. The totality of evidence from trials investigating autologous whole bone marrow infusions into patients following myocardial infarction supports the safety of this approach. In terms of efficacy, increases in ejection fraction are reported in the majority of the trials.\n\nNon-ischemic dilated cardiomyopathy is a common and problematic condition; definitive therapy in the form of heart transplantation is available to only a tiny minority of eligible patients. Cellular cardiomyoplasty for chronic heart failure has been studied less than for acute MI, but represents a potentially important alternative for this disease.",
      "DetailedDescription": "This is a Pilot Study, intended as a safety assessment prior to a full comparator study. In this Pilot Study, cells administered via the Biosense Webster MyoStar NOGA injection catheter system will be tested in 36 patients in two groups:\n\nGroup 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 X 108 (100 million) Auto-hMSCs.\n\nGroup 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 X 108 (100 million) Auto-hMSCs.\n\nThe first three (3) patients in each group (Group 1 and Group 2) will not be treated less than 5 days apart and will each undergo full evaluation for 5 days to demonstrate there is no evidence of a procedure induced myocardial infarction or myocardial perforation prior to proceeding with the treatment of further patients.\n\nPatients will be randomized in a 1:1 ratio to one of the two groups.\n\nTreatment Strategies: Autologous hMSCs vs. Allogeneic hMSCs. The Study Team will record and maintain a detailed record of injection locations.\n\nIf a patient is randomized to Groups 1 (Auto-hMSCs) and the Auto-hMSCs do not expand to the required dose of 1 X 108 cells, each injection will contain the maximum number of cells available.\n\nThe injections will be administered transendocardially during cardiac catheterization using the Biosense Webster MyoStar NOGA Catheter System.\n\nFor patients randomized to Group 1(Auto-hMSCs); the cells will be derived from a sample of the patient's bone marrow (obtained by iliac crest aspiration) approximately 4-6 weeks prior to cardiac catheterization. For patients randomized to Group 2 (Allo- hMSCs), the cells will be supplied from an allogeneic human mesenchymal stem cell source manufactured by the University of Miami. The Allo-hMSCs for patients in group 2 will be administered after all baseline assessments are completed with an expected range of 2 - 4 weeks post-randomization.\n\nFollowing cardiac catheterization and cell injections, patients will be hospitalized for a minimum of 2 days then followed at 2 weeks post-catheterization, and at month 2, 3, 6, and 12 to complete all safety and efficacy assessments."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Non-ischemic Dilated Cardiomyopathy"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Non ischemic dilated cardiomyopathy",
          "Dilated cardiomyopathy",
          "Heart failure",
          "Cardiac Stem Cell Transplantation",
          "Stem Cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "37",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Autologous hMSCs",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Autologous hMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Allogeneic hMSCs",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Allogeneic hMSCs"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Autologous hMSCs",
            "InterventionDescription": "Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous hMSCs"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Biosense Webster MyoStar NOGA Injection Catheter System."
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Allogeneic hMSCs",
            "InterventionDescription": "Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Allogeneic hMSCs"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Biosense Webster MyoStar NOGA Injection Catheter System."
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)",
            "PrimaryOutcomeDescription": "Incidence of TE-SAEs is defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise), or any other potential late effects detected and corroborated by clinical presentation, laboratory investigations, image analysis and when necessary with biopsy from suspected target sites in the body.",
            "PrimaryOutcomeTimeFrame": "One month post-catheterization"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Measurement of Changes in Peak VO2",
            "SecondaryOutcomeDescription": "Measurement of Peak oxygen consumption (Peak VO2) by treadmill determination during the 12 month follow-up period.",
            "SecondaryOutcomeTimeFrame": "Baseline, 6 month and 12 month"
          },
          {
            "SecondaryOutcomeMeasure": "Measurement of Changes in 6 Minute Walk",
            "SecondaryOutcomeDescription": "Measurement of Six-minute walk test during the 12 month follow-up period",
            "SecondaryOutcomeTimeFrame": "Baseline, 6 month and 12 month"
          },
          {
            "SecondaryOutcomeMeasure": "Measurement of Changes in Global Ejection Fraction",
            "SecondaryOutcomeDescription": "Measurement of regional left ventricular function, end diastolic and end systolic volume, measured by MRI, and or CT, and echocardiogram.",
            "SecondaryOutcomeTimeFrame": "Baseline, 6 month and 12 month"
          },
          {
            "SecondaryOutcomeMeasure": "Measurement of Changes in New York Heart Association (NYHA)",
            "SecondaryOutcomeDescription": "Measurement of New York Heart Association (NYHA) functional class during the 12 month follow-up period.",
            "SecondaryOutcomeTimeFrame": "Baseline, 6 month and 12 month"
          },
          {
            "SecondaryOutcomeMeasure": "Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire",
            "SecondaryOutcomeDescription": "Measurement of Minnesota Living with Heart Failure (MLHF) Questionnaire during the 12 month follow-up period. It measures the effects of symptoms, functional limitations, and psychological distress on an individual's quality of life. The response scale for all 21 items on the MLHF is based on a 6-point. The Maximum possible scores being 126 and the minimum 0. Higher scores indicate a worse or worsening quality of life, while lower scores or decreasing scores indicate a better quality of life.",
            "SecondaryOutcomeTimeFrame": "Baseline, 6 month and 12 month"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Major Inclusion Criteria:\n\nBe ≥ 18 and < 95 years of age.\nProvide written informed consent.\nDiagnosis of nonischemic dilated cardiomyopathy.\nBe a candidate for cardiac catheterization within 5 to 10 weeks of screening.\nBeen treated with appropriate maximal medical therapy for heart failure.\nEjection fraction below 40% and either a left ventricular end diastolic diameter (LVEDD) > 5.9cm in male subjects, an LVEDD of > 5.6cm in female subjects or left ventricular end diastolic volume index > 125 mL/m2\nBe able to undergo an MRI or CT.\n\nMajor Exclusion Criteria:\n\nBaseline glomerular filtration rate equal or < 45 ml/min/1.73m2.\nBe eligible for or require standard-of-care surgical or percutaneous intervention for the treatment of nonischemic dilated cardiomyopathy.\nPresence of a prosthetic aortic valve or heart constrictive device.\nPresence of a prosthetic mitral valve.\nPrevious myocardial infarction (MI) as documented by a clinical history that will include an elevation of cardiac enzymes and/or ECG changes consistent with MI.\nDiagnosis of nonischemic dilated cardiomyopathy due to valvular dysfunction, mitral regurgitation, tachycardia, or myocarditis.\nPrevious treatment for post-infarction left ventricular dysfunction including PCI and thrombolytic therapy.\nDocumented presence of a known LV thrombus, aortic dissection, or aortic aneurysm.\nDocumented presence of epicardial stenosis of 70% or greater in one or more major epicardial coronary arteries.\nDocumented presence of aortic stenosis (aortic stenosis graded as 1.5cm2 or less).\nDocumented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2).\nEvidence of a life-threatening arrhythmia in the absence of a defibrillator (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete second or third degree heart block in the absence of a functioning pacemaker) or QTc interval > 550 ms on screening ECG.\nAICD firing in the past 30 days prior to the procedure\nBe eligible for or require coronary artery revascularization.\nDiabetic with poorly controlled blood glucose levels and/or evidence of proliferative retinopathy.\nHave a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet values < 100,000/ul without another explanation.\nHave liver dysfunction, as evidenced by enzymes (ALT and AST) greater than three times the ULN.\nHave a coagulopathy condition = (INR > 1.3) not due to a reversible cause.\nKnown, serious radiographic contrast allergy.\nKnown allergies to penicillin or streptomycin.\nOrgan transplant recipient.\nHave a history of organ or cell transplant rejection\nClinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.\nNon-cardiac condition that limits lifespan to < 1 year.\nOn chronic therapy with immunosuppressant medication.\nSerum positive for HIV, hepatitis BsAg, or viremic hepatitis C.\nFemale patient who is pregnant, nursing, or of child-bearing potential and not using effective birth control.\nHave a history of drug or alcohol abuse within the past 24 months.\nBe currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "95 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Joshua M Hare, MD",
            "OverallOfficialAffiliation": "University of Miami",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of Miami School of Medicine",
            "LocationCity": "Miami",
            "LocationState": "Florida",
            "LocationZip": "33136",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "21415390",
            "ReferenceType": "background",
            "ReferenceCitation": "Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, Mendizabal AM, Pattany PM, Lopera GA, Fishman J, Zambrano JP, Heldman AW, Hare JM. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res. 2011 Apr 1;108(7):792-6. doi: 10.1161/CIRCRESAHA.111.242610. Epub 2011 Mar 17."
          },
          {
            "ReferencePMID": "21392602",
            "ReferenceType": "background",
            "ReferenceCitation": "Trachtenberg B, Velazquez DL, Williams AR, McNiece I, Fishman J, Nguyen K, Rouy D, Altman P, Schwarz R, Mendizabal A, Oskouei B, Byrnes J, Soto V, Tracy M, Zambrano JP, Heldman AW, Hare JM. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J. 2011 Mar;161(3):487-93. doi: 10.1016/j.ahj.2010.11.024."
          },
          {
            "ReferencePMID": "27856208",
            "ReferenceType": "background",
            "ReferenceCitation": "Hare JM, DiFede DL, Rieger AC, Florea V, Landin AM, El-Khorazaty J, Khan A, Mushtaq M, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Alfonso CE, Valasaki K, Pujol MV, Golpanian S, Ghersin E, Fishman JE, Pattany P, Gomes SA, Delgado C, Miki R, Abuzeid F, Vidro-Casiano M, Premer C, Medina A, Porras V, Hatzistergos KE, Anderson E, Mendizabal A, Mitrani R, Heldman AW. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. J Am Coll Cardiol. 2017 Feb 7;69(5):526-537. doi: 10.1016/j.jacc.2016.11.009. Epub 2016 Nov 14."
          },
          {
            "ReferencePMID": "31616309",
            "ReferenceType": "derived",
            "ReferenceCitation": "Premer C, Wanschel A, Porras V, Balkan W, Legendre-Hyldig T, Saltzman RG, Dong C, Schulman IH, Hare JM. Mesenchymal Stem Cell Secretion of SDF-1α Modulates Endothelial Function in Dilated Cardiomyopathy. Front Physiol. 2019 Sep 24;10:1182. doi: 10.3389/fphys.2019.01182. eCollection 2019."
          },
          {
            "ReferencePMID": "30005555",
            "ReferenceType": "derived",
            "ReferenceCitation": "Tompkins BA, Rieger AC, Florea V, Banerjee MN, Natsumeda M, Nigh ED, Landin AM, Rodriguez GM, Hatzistergos KE, Schulman IH, Hare JM. Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy. J Am Heart Assoc. 2018 Jul 12;7(14). pii: e008460. doi: 10.1161/JAHA.117.008460."
          },
          {
            "ReferencePMID": "25354998",
            "ReferenceType": "derived",
            "ReferenceCitation": "Mushtaq M, DiFede DL, Golpanian S, Khan A, Gomes SA, Mendizabal A, Heldman AW, Hare JM. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. J Cardiovasc Transl Res. 2014 Dec;7(9):769-80. doi: 10.1007/s12265-014-9594-0. Epub 2014 Oct 30."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Interdisciplinary Stem Cell Institute University of Miami",
            "SeeAlsoLinkURL": "http://isci.med.miami.edu"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided"
    }
  },
  "ResultsSection": {
    "ParticipantFlowModule": {
      "FlowGroupList": {
        "FlowGroup": [
          {
            "FlowGroupId": "FG000",
            "FlowGroupTitle": "Autologous hMSCs",
            "FlowGroupDescription": "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAutologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
          },
          {
            "FlowGroupId": "FG001",
            "FlowGroupTitle": "Allogeneic hMSCs",
            "FlowGroupDescription": "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAllogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
          }
        ]
      },
      "FlowPeriodList": {
        "FlowPeriod": [
          {
            "FlowPeriodTitle": "Overall Study",
            "FlowMilestoneList": {
              "FlowMilestone": [
                {
                  "FlowMilestoneType": "STARTED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "18"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "19"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "16"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "18"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "NOT COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "2"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "1"
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "BaselineCharacteristicsModule": {
      "BaselineGroupList": {
        "BaselineGroup": [
          {
            "BaselineGroupId": "BG000",
            "BaselineGroupTitle": "Autologous hMSCs",
            "BaselineGroupDescription": "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAutologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
          },
          {
            "BaselineGroupId": "BG001",
            "BaselineGroupTitle": "Allogeneic hMSCs",
            "BaselineGroupDescription": "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAllogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
          },
          {
            "BaselineGroupId": "BG002",
            "BaselineGroupTitle": "Total",
            "BaselineGroupDescription": "Total of all reporting groups"
          }
        ]
      },
      "BaselineDenomList": {
        "BaselineDenom": [
          {
            "BaselineDenomUnits": "Participants",
            "BaselineDenomCountList": {
              "BaselineDenomCount": [
                {
                  "BaselineDenomCountGroupId": "BG000",
                  "BaselineDenomCountValue": "18"
                },
                {
                  "BaselineDenomCountGroupId": "BG001",
                  "BaselineDenomCountValue": "19"
                },
                {
                  "BaselineDenomCountGroupId": "BG002",
                  "BaselineDenomCountValue": "37"
                }
              ]
            }
          }
        ]
      },
      "BaselineMeasureList": {
        "BaselineMeasure": [
          {
            "BaselineMeasureTitle": "Age, Continuous",
            "BaselineMeasureParamType": "Mean",
            "BaselineMeasureDispersionType": "Standard Deviation",
            "BaselineMeasureUnitOfMeasure": "years",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassDenomList": {
                    "BaselineClassDenom": [
                      {
                        "BaselineClassDenomUnits": "Participants",
                        "BaselineClassDenomCountList": {
                          "BaselineClassDenomCount": [
                            {
                              "BaselineClassDenomCountGroupId": "BG000",
                              "BaselineClassDenomCountValue": "18"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG001",
                              "BaselineClassDenomCountValue": "19"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG002",
                              "BaselineClassDenomCountValue": "37"
                            }
                          ]
                        }
                      }
                    ]
                  },
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "57.4",
                              "BaselineMeasurementSpread": "11.0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "54.4",
                              "BaselineMeasurementSpread": "11.5"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "55.8",
                              "BaselineMeasurementSpread": "11.2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Sex: Female, Male",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassDenomList": {
                    "BaselineClassDenom": [
                      {
                        "BaselineClassDenomUnits": "Participants",
                        "BaselineClassDenomCountList": {
                          "BaselineClassDenomCount": [
                            {
                              "BaselineClassDenomCountGroupId": "BG000",
                              "BaselineClassDenomCountValue": "18"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG001",
                              "BaselineClassDenomCountValue": "19"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG002",
                              "BaselineClassDenomCountValue": "37"
                            }
                          ]
                        }
                      }
                    ]
                  },
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Female",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "7"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "5"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "12"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Male",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "11"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "14"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "25"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassDenomList": {
                    "BaselineClassDenom": [
                      {
                        "BaselineClassDenomUnits": "Participants",
                        "BaselineClassDenomCountList": {
                          "BaselineClassDenomCount": [
                            {
                              "BaselineClassDenomCountGroupId": "BG000",
                              "BaselineClassDenomCountValue": "18"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG001",
                              "BaselineClassDenomCountValue": "19"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG002",
                              "BaselineClassDenomCountValue": "37"
                            }
                          ]
                        }
                      }
                    ]
                  },
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Hispanic or Latino",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "8"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "4"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "12"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Not Hispanic or Latino",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "10"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "15"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "25"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Unknown or Not Reported",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Race (NIH/OMB)",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassDenomList": {
                    "BaselineClassDenom": [
                      {
                        "BaselineClassDenomUnits": "Participants",
                        "BaselineClassDenomCountList": {
                          "BaselineClassDenomCount": [
                            {
                              "BaselineClassDenomCountGroupId": "BG000",
                              "BaselineClassDenomCountValue": "18"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG001",
                              "BaselineClassDenomCountValue": "19"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG002",
                              "BaselineClassDenomCountValue": "37"
                            }
                          ]
                        }
                      }
                    ]
                  },
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "American Indian or Alaska Native",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Asian",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Black or African American",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "3"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "White",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "16"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "17"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "33"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "More than one race",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Unknown or Not Reported",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Participants Injection status in the trial",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassTitle": "No",
                  "BaselineClassDenomList": {
                    "BaselineClassDenom": [
                      {
                        "BaselineClassDenomUnits": "Participants",
                        "BaselineClassDenomCountList": {
                          "BaselineClassDenomCount": [
                            {
                              "BaselineClassDenomCountGroupId": "BG000",
                              "BaselineClassDenomCountValue": "18"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG001",
                              "BaselineClassDenomCountValue": "19"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG002",
                              "BaselineClassDenomCountValue": "37"
                            }
                          ]
                        }
                      }
                    ]
                  },
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "BaselineClassTitle": "Yes",
                  "BaselineClassDenomList": {
                    "BaselineClassDenom": [
                      {
                        "BaselineClassDenomUnits": "Participants",
                        "BaselineClassDenomCountList": {
                          "BaselineClassDenomCount": [
                            {
                              "BaselineClassDenomCountGroupId": "BG000",
                              "BaselineClassDenomCountValue": "18"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG001",
                              "BaselineClassDenomCountValue": "19"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG002",
                              "BaselineClassDenomCountValue": "37"
                            }
                          ]
                        }
                      }
                    ]
                  },
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "16"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "18"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "34"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Participants Ejection Fraction % in the trial",
            "BaselineMeasureParamType": "Mean",
            "BaselineMeasureDispersionType": "Standard Deviation",
            "BaselineMeasureUnitOfMeasure": "percentage",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassDenomList": {
                    "BaselineClassDenom": [
                      {
                        "BaselineClassDenomUnits": "Participants",
                        "BaselineClassDenomCountList": {
                          "BaselineClassDenomCount": [
                            {
                              "BaselineClassDenomCountGroupId": "BG000",
                              "BaselineClassDenomCountValue": "18"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG001",
                              "BaselineClassDenomCountValue": "19"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG002",
                              "BaselineClassDenomCountValue": "37"
                            }
                          ]
                        }
                      }
                    ]
                  },
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "21.7",
                              "BaselineMeasurementSpread": "6.2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "22.5",
                              "BaselineMeasurementSpread": "6.5"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "22.1",
                              "BaselineMeasurementSpread": "6.3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Enrollment End Diastolic diameter (CM)",
            "BaselineMeasureParamType": "Mean",
            "BaselineMeasureDispersionType": "Standard Deviation",
            "BaselineMeasureUnitOfMeasure": "centimeters",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassDenomList": {
                    "BaselineClassDenom": [
                      {
                        "BaselineClassDenomUnits": "Participants",
                        "BaselineClassDenomCountList": {
                          "BaselineClassDenomCount": [
                            {
                              "BaselineClassDenomCountGroupId": "BG000",
                              "BaselineClassDenomCountValue": "18"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG001",
                              "BaselineClassDenomCountValue": "19"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG002",
                              "BaselineClassDenomCountValue": "37"
                            }
                          ]
                        }
                      }
                    ]
                  },
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "7.0",
                              "BaselineMeasurementSpread": "1.6"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "7.2",
                              "BaselineMeasurementSpread": "1.2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "7.1",
                              "BaselineMeasurementSpread": "1.4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "New York Heart Association Class",
            "BaselineMeasurePopulationDescription": "37 participants were randomized to treatment numbers and assignments but 3 did not continue with treatment and not included in the analysis.",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassDenomList": {
                    "BaselineClassDenom": [
                      {
                        "BaselineClassDenomUnits": "Participants",
                        "BaselineClassDenomCountList": {
                          "BaselineClassDenomCount": [
                            {
                              "BaselineClassDenomCountGroupId": "BG000",
                              "BaselineClassDenomCountValue": "16"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG001",
                              "BaselineClassDenomCountValue": "18"
                            },
                            {
                              "BaselineClassDenomCountGroupId": "BG002",
                              "BaselineClassDenomCountValue": "34"
                            }
                          ]
                        }
                      }
                    ]
                  },
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Class I - no limitation",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "6"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "4"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "10"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Class II - Slight Limitation of Physical Activity",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "8"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "9"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "17"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Class III - Marked Limitation of Physical Activity",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "5"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "7"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Class IV -Inability to carry on physical activity",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "OutcomeMeasuresModule": {
      "OutcomeMeasureList": {
        "OutcomeMeasure": [
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)",
            "OutcomeMeasureDescription": "Incidence of TE-SAEs is defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise), or any other potential late effects detected and corroborated by clinical presentation, laboratory investigations, image analysis and when necessary with biopsy from suspected target sites in the body.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "One month post-catheterization",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Autologous hMSCs",
                  "OutcomeGroupDescription": "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAutologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Allogeneic hMSCs",
                  "OutcomeGroupDescription": "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAllogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "16"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "18"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Upper respiratory tract infection",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "1"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Ventricular tachycardia",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Device Pacing issue",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Measurement of Changes in Peak VO2",
            "OutcomeMeasureDescription": "Measurement of Peak oxygen consumption (Peak VO2) by treadmill determination during the 12 month follow-up period.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Mean",
            "OutcomeMeasureDispersionType": "Standard Deviation",
            "OutcomeMeasureUnitOfMeasure": "ml/kg/min",
            "OutcomeMeasureTimeFrame": "Baseline, 6 month and 12 month",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Autologous hMSCs",
                  "OutcomeGroupDescription": "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAutologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Allogeneic hMSCs",
                  "OutcomeGroupDescription": "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAllogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "16"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "18"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Peak VO2 (Baseline)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "16.0",
                              "OutcomeMeasurementSpread": "5.13"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "17.9",
                              "OutcomeMeasurementSpread": "5.17"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Peak VO2 (6 months)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "15.5",
                              "OutcomeMeasurementSpread": "6.62"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "17.6",
                              "OutcomeMeasurementSpread": "3.55"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Peak VO2 (1 year)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "16.4",
                              "OutcomeMeasurementSpread": "3.92"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "20.1",
                              "OutcomeMeasurementSpread": "5.10"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Measurement of Changes in 6 Minute Walk",
            "OutcomeMeasureDescription": "Measurement of Six-minute walk test during the 12 month follow-up period",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Mean",
            "OutcomeMeasureDispersionType": "Standard Deviation",
            "OutcomeMeasureUnitOfMeasure": "meters",
            "OutcomeMeasureTimeFrame": "Baseline, 6 month and 12 month",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Autologous hMSCs",
                  "OutcomeGroupDescription": "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAutologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Allogeneic hMSCs",
                  "OutcomeGroupDescription": "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAllogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "16"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "18"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "6 minute walk (Baseline)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "416.4",
                              "OutcomeMeasurementSpread": "105.74"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "427.2",
                              "OutcomeMeasurementSpread": "67.35"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "6 minute walk (6 months)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "384.2",
                              "OutcomeMeasurementSpread": "106.96"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "438.7",
                              "OutcomeMeasurementSpread": "106.53"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "6 minute walk (1 year)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "32.3",
                              "OutcomeMeasurementSpread": "12.71"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "35.1",
                              "OutcomeMeasurementSpread": "13.59"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Measurement of Changes in Global Ejection Fraction",
            "OutcomeMeasureDescription": "Measurement of regional left ventricular function, end diastolic and end systolic volume, measured by MRI, and or CT, and echocardiogram.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Mean",
            "OutcomeMeasureDispersionType": "Standard Deviation",
            "OutcomeMeasureUnitOfMeasure": "% ratio of the SV to Global EDV",
            "OutcomeMeasureTimeFrame": "Baseline, 6 month and 12 month",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Autologous hMSCs",
                  "OutcomeGroupDescription": "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAutologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Allogeneic hMSCs",
                  "OutcomeGroupDescription": "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAllogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "16"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "18"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Global ejection fraction (Baseline)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "25.2",
                              "OutcomeMeasurementSpread": "10.49"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "37.6",
                              "OutcomeMeasurementSpread": "9.03"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Global ejection fraction (1 year)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "32.3",
                              "OutcomeMeasurementSpread": "12.71"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "35.1",
                              "OutcomeMeasurementSpread": "13.59"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Measurement of Changes in New York Heart Association (NYHA)",
            "OutcomeMeasureDescription": "Measurement of New York Heart Association (NYHA) functional class during the 12 month follow-up period.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "Baseline, 6 month and 12 month",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Autologous hMSCs",
                  "OutcomeGroupDescription": "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAutologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Allogeneic hMSCs",
                  "OutcomeGroupDescription": "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAllogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "18"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "19"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "NYHA Class 1 (Baseline)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "6"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "NYHA Class 2 (Baseline)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "8"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "9"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "NYHA Class 3 (Baseline)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "5"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "NYHA Class 1 (6 month)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "8"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "12"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "NYHA Class 2 (6 month)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "6"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "NYHA Class 3 (6 month)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "1"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "NYHA Class 1 (12 month)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "7"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "14"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "NYHA Class 2 (12 month)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "NYHA Class 3 (12 month)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire",
            "OutcomeMeasureDescription": "Measurement of Minnesota Living with Heart Failure (MLHF) Questionnaire during the 12 month follow-up period. It measures the effects of symptoms, functional limitations, and psychological distress on an individual's quality of life. The response scale for all 21 items on the MLHF is based on a 6-point. The Maximum possible scores being 126 and the minimum 0. Higher scores indicate a worse or worsening quality of life, while lower scores or decreasing scores indicate a better quality of life.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Median",
            "OutcomeMeasureDispersionType": "Full Range",
            "OutcomeMeasureUnitOfMeasure": "scores on a scale",
            "OutcomeMeasureTimeFrame": "Baseline, 6 month and 12 month",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Autologous hMSCs",
                  "OutcomeGroupDescription": "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAutologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Allogeneic hMSCs",
                  "OutcomeGroupDescription": "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAllogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "16"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "18"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "MLHF (Baseline)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "30.5",
                              "OutcomeMeasurementLowerLimit": "5.0",
                              "OutcomeMeasurementUpperLimit": "80.0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "38.0",
                              "OutcomeMeasurementLowerLimit": "10.0",
                              "OutcomeMeasurementUpperLimit": "82.0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "MLHF (6 month)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "35",
                              "OutcomeMeasurementLowerLimit": "0.0",
                              "OutcomeMeasurementUpperLimit": "87.0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "18",
                              "OutcomeMeasurementLowerLimit": "0.0",
                              "OutcomeMeasurementUpperLimit": "68.0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "MLHF (12 month)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "9.0",
                              "OutcomeMeasurementLowerLimit": "0.0",
                              "OutcomeMeasurementUpperLimit": "41.0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "12.0",
                              "OutcomeMeasurementLowerLimit": "0.0",
                              "OutcomeMeasurementUpperLimit": "51.0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "AdverseEventsModule": {
      "EventsFrequencyThreshold": "0",
      "EventsTimeFrame": "These AE's were collected over a period of 1 year from the subject signing the consent form.",
      "EventGroupList": {
        "EventGroup": [
          {
            "EventGroupId": "EG000",
            "EventGroupTitle": "Autologous hMSCs",
            "EventGroupDescription": "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAutologous hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.",
            "EventGroupDeathsNumAffected": "2",
            "EventGroupDeathsNumAtRisk": "18",
            "EventGroupSeriousNumAffected": "6",
            "EventGroupSeriousNumAtRisk": "18",
            "EventGroupOtherNumAffected": "4",
            "EventGroupOtherNumAtRisk": "18"
          },
          {
            "EventGroupId": "EG001",
            "EventGroupTitle": "Allogeneic hMSCs",
            "EventGroupDescription": "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.\n\nAllogeneic hMSCs: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:\n\nGroup 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.",
            "EventGroupDeathsNumAffected": "0",
            "EventGroupDeathsNumAtRisk": "19",
            "EventGroupSeriousNumAffected": "6",
            "EventGroupSeriousNumAtRisk": "19",
            "EventGroupOtherNumAffected": "7",
            "EventGroupOtherNumAtRisk": "19"
          }
        ]
      },
      "SeriousEventList": {
        "SeriousEvent": [
          {
            "SeriousEventTerm": "Ventricular tachycardia",
            "SeriousEventOrganSystem": "Cardiac disorders",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "1-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Upper respiratory tract infection",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "1-month sae",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Device Pacing issue",
            "SeriousEventOrganSystem": "Product Issues",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "1-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Arrhythmia",
            "SeriousEventOrganSystem": "Cardiac disorders",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "6-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Cardiac failure",
            "SeriousEventOrganSystem": "Cardiac disorders",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "6-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "3",
                  "SeriousEventStatsNumAffected": "2",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Coronary artery disease",
            "SeriousEventOrganSystem": "Cardiac disorders",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "6-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Ventricular tachycardia",
            "SeriousEventOrganSystem": "Cardiac disorders",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "6-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Gatrooesophageal reflux disease",
            "SeriousEventOrganSystem": "Gastrointestinal disorders",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "6-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Upper respiratory tract infection",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "6-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Subdural heamatoma",
            "SeriousEventOrganSystem": "Injury, poisoning and procedural complications",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "6-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Syncope",
            "SeriousEventOrganSystem": "Nervous system disorders",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "6-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Device pacing issues",
            "SeriousEventOrganSystem": "Product Issues",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "6-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Dyspnoea",
            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "6-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Angioedema",
            "SeriousEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "6-month SAE",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "18"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "19"
                }
              ]
            }
          }
        ]
      },
      "OtherEventList": {
        "OtherEvent": [
          {
            "OtherEventTerm": "Anemia",
            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment Emergent Adverse event at one-month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Mitral valve incompetence",
            "OtherEventOrganSystem": "Cardiac disorders",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment Emergent AE at 1-month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Ventricular tachycardia",
            "OtherEventOrganSystem": "Cardiac disorders",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Adverse drug reaction",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Chest Discomfort",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Upper respiratory tract infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Vulvovaginal mycotic infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Electrocardiogram abnormal",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Weight increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dizziness",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Migraine",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Device pacing issue",
            "OtherEventOrganSystem": "Product Issues",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dyspnoea",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Wheezing",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Implantable defibrillator insertion",
            "OtherEventOrganSystem": "Surgical and medical procedures",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Treatment emergent adverse event at 1 month",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "18"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "19"
                }
              ]
            }
          }
        ]
      }
    },
    "MoreInfoModule": {
      "CertainAgreement": {
        "AgreementPISponsorEmployee": "Yes"
      },
      "PointOfContact": {
        "PointOfContactTitle": "Joshua M. Hare, MD",
        "PointOfContactOrganization": "ISCI / University of Miami Miller School of Medicine",
        "PointOfContactEMail": "JHare@med.miami.edu",
        "PointOfContactPhone": "305-243-5579"
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009202",
            "ConditionMeshTerm": "Cardiomyopathies"
          },
          {
            "ConditionMeshId": "D000002311",
            "ConditionMeshTerm": "Cardiomyopathy, Dilated"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000006331",
            "ConditionAncestorTerm": "Heart Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000006332",
            "ConditionAncestorTerm": "Cardiomegaly"
          },
          {
            "ConditionAncestorId": "D000083083",
            "ConditionAncestorTerm": "Laminopathies"
          },
          {
            "ConditionAncestorId": "D000030342",
            "ConditionAncestorTerm": "Genetic Diseases, Inborn"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8573",
            "ConditionBrowseLeafName": "Heart Failure",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11306",
            "ConditionBrowseLeafName": "Cardiomyopathies",
            "ConditionBrowseLeafAsFound": "Cardiomyopathy",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4719",
            "ConditionBrowseLeafName": "Cardiomyopathy, Dilated",
            "ConditionBrowseLeafAsFound": "Dilated Cardiomyopathy",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8571",
            "ConditionBrowseLeafName": "Heart Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8572",
            "ConditionBrowseLeafName": "Cardiomegaly",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M2393",
            "ConditionBrowseLeafName": "Laminopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22839",
            "ConditionBrowseLeafName": "Genetic Diseases, Inborn",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T1876",
            "ConditionBrowseLeafName": "Dilated Cardiomyopathy",
            "ConditionBrowseLeafAsFound": "Dilated Cardiomyopathy",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}